Get the Stockscreener App
4.50
2.39%
-0.11
After Hours:
4.50
Ardelyx Inc stock is traded at $4.50, with a volume of 3.04M.
It is down -2.39% in the last 24 hours and up +25.00% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$4.61
Open:
$4.63
24h Volume:
3.04M
Relative Volume:
0.56
Market Cap:
$1.08B
Revenue:
$251.85M
Net Income/Loss:
$-72.58M
P/E Ratio:
-14.36
EPS:
-0.3134
Net Cash Flow:
$-63.80M
1W Performance:
+0.45%
1M Performance:
+25.00%
6M Performance:
-15.89%
1Y Performance:
-24.37%
1-Day Range:
$4.49
$4.6699
1-Week Range:
$4.34
$4.715
52-Week Range:
$3.21
$7.18
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
4.50 | 1.07B | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.20 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.96 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.12 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
555.96 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.70 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
This Small-Cap Stock Could 10x By 2030, But It’s Not For The Faint Of Heart - Barchart.com
Wedbush Raises Price Target on Ardelyx to $13 From $11, Keeps Outperform Rating - MarketScreener
Jefferies Maintains a Buy Rating on Ardelyx (ARDX) With an $8 Price Target - MSN
Lobbying Update: $50,000 of ARDELYX INC. lobbying was just disclosed - Quiver Quantitative
There's No Escaping Ardelyx, Inc.'s (NASDAQ:ARDX) Muted Revenues Despite A 26% Share Price Rise - simplywall.st
Ardelyx Faces An Uphill Battle Despite Oral Arguments Set In XPHOZAH Appeal (NASDAQ:ARDX) - Seeking Alpha
Cantor Fitzgerald reiterates Overweight rating on Ardelyx stock - Investing.com
Cantor Fitzgerald reiterates Overweight rating on Ardelyx stock By Investing.com - Investing.com Nigeria
Ardelyx (ARDX) Appoints New Chief Business and HR Officers - MSN
Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024 – ARDX - ACCESS Newswire
Ardelyx amends loan agreement to draw $50 million and secures future options - Investing.com
Ardelyx: 'Hold' With Caution As Major Inflection Point Approaches (NASDAQ:ARDX) - Seeking Alpha
Ardelyx spike attributed to Xphozah legal update - MSN
(ARDX) Trading Signals - news.stocktradersdaily.com
A biopharma bolsters patient centricity and trial diversity goals through newly created role - Yahoo Finance
10 Best Healthcare Penny Stocks to Buy According to Analysts - Insider Monkey
Two Beaten-Down Biotech Stocks See Big Insider Buys - Barron's
H.C. Wainwright Initiates Coverage of Ardelyx (ARDX) Stock, Gives Buy - MSN
Leerink Partners Maintains a Buy Rating on Ardelyx (ARDX) With a $10 PT - MSN
13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc.ARDX - PR Newswire
Director David Mott Acquires 200,000 Shares of Ardelyx Inc (ARDX) - GuruFocus
Ardelyx Stockholders Approve Equity Plan Amendment - TipRanks
ARDX Gains Attention with HC Wainwright & Co. Buy Rating | ARDX Stock News - GuruFocus
H.C. Wainwright assumes coverage on Ardelyx stock with buy rating By Investing.com - Investing.com India
Ardelyx (ARDX) Receives Positive Coverage with Buy Rating and $10 Target | ARDX Stock News - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. ... - Bluefield Daily Telegraph
Hedge Fund and Insider Trading News: Paul Tudor Jones, Divya Nettimi, Scott Bessent, Marshall Wace, Warren Buffett, Rokos Capital Management, Ardelyx Inc (ARDX), Ralph Lauren Corp (RL), and More - Insider Monkey
Ardelyx director David Mott acquires $737,260 in stock By Investing.com - Investing.com South Africa
Ardelyx director David Mott acquires $737,260 in stock - Investing.com
ARDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
How to Take Advantage of moves in (ARDX) - news.stocktradersdaily.com
Ardelyx is hiring: Director, Marketing in New York at Ardelyx Job - Mediabistro
Ardelyx names new chief business and human resources officers - The Pharma Letter
Transcript : Ardelyx, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - MarketScreener
Ardelyx at Jefferies Conference: Strategic Growth and Market Challenges By Investing.com - Investing.com India
Ardelyx at Jefferies Conference: Strategic Growth and Market Challenges - Investing.com
Ardelyx is hiring: Director, Marketing in Waltham at Ardelyx Job - Mediabistro
Ardelyx reshuffles leadership, adds new HR chief By Investing.com - Investing.com South Africa
Ardelyx appoints Mike Kelliher Chief Business Officer - TipRanks
Ardelyx Promotes Mike Kelliher to Chief Business Officer - marketscreener.com
Ardelyx reshuffles leadership, adds new HR chief - Investing.com Australia
Ardelyx (ARDX) Appoints New Leadership in Strategic Roles | ARDX Stock News - GuruFocus
Ardelyx Appoints Mike Kelliher Chief Business Officer - marketscreener.com
Ardelyx Appoints Mike Kelliher Chief Business Officer and James - GuruFocus
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer - The Manila Times
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer | ARDX Stock News - GuruFocus
Ardelyx Expands Leadership: Strategic Promotion and Key Executive Hire Signal Growth Push - Stock Titan
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):